financetom
Business
financetom
/
Business
/
Vedanta’s Athena Chhattisgarh Power deal fails to cheer Street as shares slip into the red after rising 2%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vedanta’s Athena Chhattisgarh Power deal fails to cheer Street as shares slip into the red after rising 2%
Jul 7, 2022 9:35 AM

Shares of Vedanta rose around 2 percent on Friday after the metal major acquired the entire stake in Athena Chhattisgarh Power for Rs 564.7 crore. However, the stock could not hold on to initial gains and slipped into the red.

Share Market Live

NSE

At 1514 IST, shares of Vedanta were trading down 1.8 percent at Rs 223.7 on the BSE.

"Athena Chhattisgarh Power is a 1,200MW coal-based power plant located at Jhanjgir Champa district, Chhattisgarh. The Plant has 2 units of 600MW each. Unit 1 and Unit 2 are 80 percent and 30 percent complete respectively and therefore, the company has never been operational," the company said in a BSE filing.

"The company was admitted under Corporate Insolvency Resolution Process (CIRP) on May 15, 2019, and on May 13, 2021, NCLT Hyderabad bench directed initiation of the liquidation process of the company," it said.

Also Read: Tianqi Lithium raises $1.7 billion in biggest Hong Kong listing this year

The acquisition will fulfil the power requirement for Vedanta’s aluminium business, and via vertical integration add synergies by providing a cost advantage pertaining to power consumption, Vedanta said.

The acquisition is estimated to be completed in the current financial year.

The plant is well connected to national highways and railway stations and is also located in close proximity to its water source, the Mahanadi river, it added.

Catch up on all LIVE stock market highlights here.

(Edited by : Shoma Bhattacharjee)

First Published:Jul 7, 2022 6:35 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US Transportation Sec'y Duffy requests meeting with Boeing CEO on safety
US Transportation Sec'y Duffy requests meeting with Boeing CEO on safety
Feb 13, 2025
WASHINGTON (Reuters) - U.S. Transportation Secretary Sean Duffy said on Thursday he has asked the CEO of Boeing to come to Washington, D.C., as soon as possible to discuss quality and safety issues at the company. Following that, I will visit Boeing myself to evaluate firsthand the measures being implemented to ensure its planes meet the highest safety standards, Duffy...
US Transportation Sec'y Duffy requests meeting with Boeing CEO on safety
US Transportation Sec'y Duffy requests meeting with Boeing CEO on safety
Feb 13, 2025
WASHINGTON, Feb 13 (Reuters) - U.S. Transportation Secretary Sean Duffy said on Thursday he has asked the CEO of Boeing ( BA ) to come to Washington, D.C., as soon as possible to discuss quality and safety issues at the company. Following that, I will visit Boeing ( BA ) myself to evaluate firsthand the measures being implemented to ensure...
Toyota Motor to Recall Sienna Minivans
Toyota Motor to Recall Sienna Minivans
Feb 13, 2025
03:48 PM EST, 02/13/2025 (MT Newswires) -- Toyota Motor ( TM ) said Thursday it is recalling Sienna minivan models from 2021 to 2025 in North America, Asia, and other regions, including roughly 168,000 in the US. The automaker said bolts connecting the split 60/40 third-row seat backs may not be tightened to the proper safety standards, which could prevent...
ImmunityBio's Application for Anktiva Approved for Review in UK
ImmunityBio's Application for Anktiva Approved for Review in UK
Feb 13, 2025
03:37 PM EST, 02/13/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Thursday that the UK's Medicines and Healthcare Products Regulatory Agency accepted its marketing authorization application for Anktiva in combination with bacillus Calmette-Guerin to treat certain patients with non-muscle invasive bladder cancer. The application covers patients who do not respond to bacillus Calmette-Guerin and are with carcinoma in situ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved